CN1430514A - 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 - Google Patents
加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 Download PDFInfo
- Publication number
- CN1430514A CN1430514A CN01807334A CN01807334A CN1430514A CN 1430514 A CN1430514 A CN 1430514A CN 01807334 A CN01807334 A CN 01807334A CN 01807334 A CN01807334 A CN 01807334A CN 1430514 A CN1430514 A CN 1430514A
- Authority
- CN
- China
- Prior art keywords
- dosage
- days
- galantamine
- treatment
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims abstract description 121
- 229960003980 galantamine Drugs 0.000 title claims abstract description 60
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 208000024827 Alzheimer disease Diseases 0.000 title abstract description 7
- 238000000034 method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 12
- 230000003203 everyday effect Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000017667 Chronic Disease Diseases 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 31
- 239000000902 placebo Substances 0.000 description 31
- 230000006399 behavior Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 230000008859 change Effects 0.000 description 19
- 230000002411 adverse Effects 0.000 description 17
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 8
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 8
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 5
- 206010042772 syncope Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 238000007492 two-way ANOVA Methods 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 241000234271 Galanthus Species 0.000 description 2
- 241000234283 Galanthus nivalis Species 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000006998 cognitive state Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940006388 galantamine 8 mg Drugs 0.000 description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 230000007074 memory dysfunction Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 240000006487 Aciphylla squarrosa Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 235000015256 Chionanthus virginicus Nutrition 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 101710083761 Cholinesterase Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- BLGKYYVFGMKTEZ-QVCIKPHISA-N D-galactosyl-N-hexadecanoylsphinganine Chemical group CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BLGKYYVFGMKTEZ-QVCIKPHISA-N 0.000 description 1
- SNPQGCDJHZAVOB-LUUMFRNDSA-N D-galactosyl-N-tetracosanoylsphinganine Chemical group CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-LUUMFRNDSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 102100039554 Galectin-8 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101000887168 Gallus gallus Gallinacin-8 Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DITOENWBJBNZSL-UHFFFAOYSA-N O-methyl-hippeastrine Natural products C1=C2C3C4N(C)CCC4=CC(OC)C3OC(=O)C2=CC2=C1OCO2 DITOENWBJBNZSL-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101100532451 Rattus norvegicus Slc22a17 gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- -1 tertiary amine alkaloid Chemical class 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19425900P | 2000-04-03 | 2000-04-03 | |
US60/194,259 | 2000-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1430514A true CN1430514A (zh) | 2003-07-16 |
Family
ID=22716898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01807334A Pending CN1430514A (zh) | 2000-04-03 | 2001-03-28 | 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1272192A2 (xx) |
JP (1) | JP2003528913A (xx) |
KR (1) | KR20020086911A (xx) |
CN (1) | CN1430514A (xx) |
AU (2) | AU6584401A (xx) |
BG (1) | BG107093A (xx) |
BR (1) | BR0109770A (xx) |
CA (1) | CA2310926C (xx) |
CZ (1) | CZ20023543A3 (xx) |
EE (1) | EE200200554A (xx) |
HR (1) | HRP20020778A2 (xx) |
HU (1) | HUP0300566A3 (xx) |
IL (1) | IL152061A0 (xx) |
MX (1) | MXPA02009777A (xx) |
NO (1) | NO20024746L (xx) |
PL (1) | PL361272A1 (xx) |
RU (1) | RU2002129298A (xx) |
SK (1) | SK15422002A3 (xx) |
WO (1) | WO2001074339A2 (xx) |
ZA (1) | ZA200207935B (xx) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105228638A (zh) * | 2013-03-07 | 2016-01-06 | 贝尔毕贝希尔私人有限公司 | 富含加兰他敏的凤蝶朱顶红的提取物 |
CN107847504A (zh) * | 2015-05-18 | 2018-03-27 | 斯奈普泰克发展有限责任公司 | 淀粉状蛋白β的加兰他敏清除 |
WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
BRPI0412919A (pt) | 2003-07-25 | 2006-09-26 | Hoffmann La Roche | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
MX2010010460A (es) | 2008-03-27 | 2010-12-15 | Chase Pharmaceuticals Corp | Uso y composicion para tratar la demencia. |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
HUP0104778A3 (en) * | 1998-12-24 | 2004-05-28 | Janssen Pharmaceutica Nv | Controlled release galantamine composition |
CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105228638A (zh) * | 2013-03-07 | 2016-01-06 | 贝尔毕贝希尔私人有限公司 | 富含加兰他敏的凤蝶朱顶红的提取物 |
CN107847504A (zh) * | 2015-05-18 | 2018-03-27 | 斯奈普泰克发展有限责任公司 | 淀粉状蛋白β的加兰他敏清除 |
WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Also Published As
Publication number | Publication date |
---|---|
PL361272A1 (en) | 2004-10-04 |
EP1272192A2 (en) | 2003-01-08 |
BG107093A (bg) | 2003-06-30 |
AU2001265844B2 (en) | 2005-04-14 |
MXPA02009777A (es) | 2003-03-27 |
HUP0300566A3 (en) | 2004-10-28 |
AU6584401A (en) | 2001-10-15 |
KR20020086911A (ko) | 2002-11-20 |
BR0109770A (pt) | 2003-02-04 |
NO20024746D0 (no) | 2002-10-02 |
CZ20023543A3 (cs) | 2003-03-12 |
CA2310926A1 (en) | 2000-10-04 |
JP2003528913A (ja) | 2003-09-30 |
ZA200207935B (en) | 2004-01-30 |
EE200200554A (et) | 2004-04-15 |
RU2002129298A (ru) | 2004-03-27 |
HRP20020778A2 (en) | 2004-04-30 |
IL152061A0 (en) | 2003-05-29 |
NO20024746L (no) | 2002-11-28 |
SK15422002A3 (sk) | 2003-04-01 |
WO2001074339A2 (en) | 2001-10-11 |
HUP0300566A2 (hu) | 2003-06-28 |
CA2310926C (en) | 2002-10-15 |
WO2001074339A3 (en) | 2002-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cook Jr et al. | Fluoxetine treatment of children and adults with autistic disorder and mental retardation | |
CN1084618C (zh) | 5-羟色胺拮抗剂的新应用 | |
Silver et al. | Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder | |
Heinrich et al. | Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial | |
Bruera et al. | Management of specific symptom complexes in patients receiving palliative care | |
JP6912574B2 (ja) | 機能低下を治療するためのプリドピジンの使用 | |
CN102026980A (zh) | 作为nk3拮抗剂的异喹啉酮衍生物 | |
CN1350453A (zh) | 治疗运动诱导型哮喘的方法 | |
WO2010093838A1 (en) | Compostions and methods for using aminopyridines | |
Matsuda et al. | Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy | |
Su et al. | Fixed-dose combination chemotherapy (Rifater®/Rifinah®) for active pulmonary tuberculosis in Taiwan: a two-year follow-up | |
CN1430514A (zh) | 加兰他敏用于治疗与阿耳茨海默氏病有关的神经精神病行为的用途 | |
Matsumoto et al. | Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women | |
Yan et al. | Mercury poisoning presenting with hypertension: Report of 2 cases | |
JP2004513874A (ja) | 副作用を軽減する効果的なガランタミンの投薬計画 | |
DE60216457T2 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
CN118267382A (zh) | 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗 | |
CN1349403A (zh) | 治疗copd的方法 | |
US20230000799A1 (en) | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy | |
Larone et al. | Exserohilum rostratum: anatomy of a national outbreak of fungal meningitis | |
AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
CN100335074C (zh) | 一种治疗中风病的中药口服液 | |
Cahaya et al. | Incidence of Orthostatic Hypotension in Schizophrenic Patients Using Antipsychotics at Sambang Lihum Mental Health Hospital, South Kalimantan | |
Aakhus et al. | Single session educational programme for caregivers of psychogeriatric in‐patients–results from a randomised controlled pilot study | |
WO2023233570A1 (ja) | 点鼻用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1055402 Country of ref document: HK |